New York, NY — February 15, 2018 — Transparency Life Sciences (TLS), a pioneer in digital drug
development clinical services, today announced completion of a $5.0 million Series A financing led by
venture investor New Ventures III. Existing private investors also participated. TLS will use the new
financing to expand the company’s technology platform and clinical operations infrastructure, and drive
commercialization of its integrated digital approach to clinical drug development. New Ventures’ Richard
Warburg, PhD and Harry Glorikian will join the TLS Board of Directors.
“TLS was among the first to envision how digital technologies could transform a legacy clinical trial
system that is inefficient and ineffective,” said Tomasz Sablinski, MD, PhD, co-founder and CEO of TLS.
More at: http://transparencyls.com/files/PDF/TLS_Series_A.pdf
